[go: up one dir, main page]

IS8150A - Samnotkun hamla á NMDA-viðtaka og sérhæfðum serótónin endurupptöku hamla (SSRI) til meðhöndlunar á þunglyndi og öðrum lindisröskunum - Google Patents

Samnotkun hamla á NMDA-viðtaka og sérhæfðum serótónin endurupptöku hamla (SSRI) til meðhöndlunar á þunglyndi og öðrum lindisröskunum

Info

Publication number
IS8150A
IS8150A IS8150A IS8150A IS8150A IS 8150 A IS8150 A IS 8150A IS 8150 A IS8150 A IS 8150A IS 8150 A IS8150 A IS 8150A IS 8150 A IS8150 A IS 8150A
Authority
IS
Iceland
Prior art keywords
ssris
specialized
depression
treatment
receptor antagonists
Prior art date
Application number
IS8150A
Other languages
English (en)
Inventor
Samoriski Gary
Gupta Sandeep
Original Assignee
Forest Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Laboratories, Inc. filed Critical Forest Laboratories, Inc.
Publication of IS8150A publication Critical patent/IS8150A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS8150A 2003-05-27 2005-11-25 Samnotkun hamla á NMDA-viðtaka og sérhæfðum serótónin endurupptöku hamla (SSRI) til meðhöndlunar á þunglyndi og öðrum lindisröskunum IS8150A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47363903P 2003-05-27 2003-05-27
PCT/US2004/016959 WO2005000216A2 (en) 2003-05-27 2004-05-27 Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders

Publications (1)

Publication Number Publication Date
IS8150A true IS8150A (is) 2005-11-25

Family

ID=33551455

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8150A IS8150A (is) 2003-05-27 2005-11-25 Samnotkun hamla á NMDA-viðtaka og sérhæfðum serótónin endurupptöku hamla (SSRI) til meðhöndlunar á þunglyndi og öðrum lindisröskunum

Country Status (16)

Country Link
US (2) US20050014743A1 (is)
EP (2) EP2260844A1 (is)
JP (1) JP2007500238A (is)
KR (2) KR20060030469A (is)
CN (1) CN1794981A (is)
AU (1) AU2004251636B2 (is)
CA (1) CA2528622C (is)
EA (1) EA010430B1 (is)
IL (1) IL172163A (is)
IS (1) IS8150A (is)
MX (1) MXPA05012493A (is)
NO (1) NO20056134L (is)
RS (1) RS20050851A (is)
UA (1) UA80055C2 (is)
WO (1) WO2005000216A2 (is)
ZA (1) ZA200509542B (is)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
US20060223857A1 (en) * 2003-08-21 2006-10-05 Michael Didriksen Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
ITTO20050301A1 (it) * 2005-05-05 2006-11-06 Errekappa Euroterapici Spa Formulazioni liquide orali contenenti citalopram
ZA200711123B (en) 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
WO2007061868A2 (en) * 2005-11-17 2007-05-31 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
KR100769700B1 (ko) * 2007-06-15 2007-10-23 손춘남 배압제거 역류방지 장치
EP2203163B1 (en) * 2007-09-12 2014-08-27 Merz Pharma GmbH & Co. KGaA Titration package for neramexane and its use in the treatment of an inner ear disorder
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
NZ589764A (en) * 2008-05-09 2012-10-26 Univ Emory NMDA receptor antagonists for the treatment of neuropsychiatric disorders
MX2011006353A (es) 2008-12-19 2011-07-13 Merz Pharma Gmbh & Co Kgaa Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos.
TWI432188B (zh) * 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
IT1396556B1 (it) * 2009-02-11 2012-12-14 Serra Uso di memantina per il trattamento di disturbi dell umore
WO2010126527A1 (en) * 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders
US20120123166A1 (en) * 2009-06-29 2012-05-17 Merz Pharma Gmbh & Co. Kgaa Method of preparing 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
BR112012022478B1 (pt) 2010-03-10 2021-09-21 Probiodrug Ag Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2012111011A2 (en) * 2011-02-16 2012-08-23 Nir Barak Low dosage combinations of fluoxetine and reboxetine for treating obesity
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
KR20140069120A (ko) * 2011-09-13 2014-06-09 노파르티스 아게 S1p 수용체 조절제를 포함하는 조합물
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
KR101484405B1 (ko) * 2013-08-14 2015-01-19 서울대학교산학협력단 Ｎｉｎｊｕｒｉｎ１ 결핍 유래의 강박증 예방 또는 치료용 약학적 조성물
MX2016014581A (es) * 2014-05-06 2018-02-16 Univ Northwestern Composiciones de compuestos que modulan nmdar.
PL3297628T3 (pl) * 2015-05-18 2021-12-06 Sensorion Azasetron do stosowania w leczeniu niedosłuchu
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
KR102089737B1 (ko) * 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (is) 1972-04-20 1973-10-23
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5366738A (en) 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4849222A (en) 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
DE58905637D1 (de) * 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
EP0724432B1 (en) 1993-10-22 2002-09-18 Genentech, Inc. Methods and compositions for microencapsulation of antigens for use as vaccines
EP0980247A1 (en) * 1997-05-07 2000-02-23 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
US6071966A (en) 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
JP3963488B2 (ja) * 1997-06-30 2007-08-22 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツンク ウント コンパニー コマンディゲゼルシャフト アウフ アクチェン １−アミノ−アルキルシクロヘキサンｎｍｄａ受容体拮抗薬
GB9802225D0 (en) * 1998-02-02 1998-04-01 Cerebrus Ltd Chemical compounds
DE69935331T2 (de) * 1998-07-13 2007-10-31 NPS Pharmaceuticals, Inc., Salt Lake City Verfahren und verbindungen zur behandlung der depression
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
TW593223B (en) 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
MXPA05000294A (es) * 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
EP1595535A2 (en) * 2002-12-23 2005-11-16 Osmotica Costa Rica Sociedad Anonima Delivery device containing venlafaxine and memantine and use method thereof
AR043467A1 (es) * 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
AU2005215775B2 (en) * 2004-02-13 2011-02-03 Neuromolecular, Inc. Combination of a NMDA receptor antagonist and an anti-depressive drug MAO-inhibitor or a GADPH-inhibitor for the treatment of psychiatric conditions

Also Published As

Publication number Publication date
RS20050851A (sr) 2008-04-04
ZA200509542B (en) 2007-03-28
KR20070104480A (ko) 2007-10-25
NO20056134L (no) 2006-02-27
EP1631274A2 (en) 2006-03-08
JP2007500238A (ja) 2007-01-11
AU2004251636B2 (en) 2006-11-09
WO2005000216A2 (en) 2005-01-06
EP2260844A1 (en) 2010-12-15
EA010430B1 (ru) 2008-08-29
CA2528622C (en) 2010-08-03
EA200501867A1 (ru) 2006-06-30
CN1794981A (zh) 2006-06-28
US20050014743A1 (en) 2005-01-20
UA80055C2 (en) 2007-08-10
EP1631274A4 (en) 2007-03-28
CA2528622A1 (en) 2005-01-06
WO2005000216A3 (en) 2005-11-10
IL172163A (en) 2012-01-31
AU2004251636A1 (en) 2005-01-06
WO2005000216A8 (en) 2005-12-22
KR20060030469A (ko) 2006-04-10
MXPA05012493A (es) 2006-05-25
US20100076073A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
IS8150A (is) Samnotkun hamla á NMDA-viðtaka og sérhæfðum serótónin endurupptöku hamla (SSRI) til meðhöndlunar á þunglyndi og öðrum lindisröskunum
IS6003A (is) Mónóamín endurupptökulatar til meðhöndlunar á truflunum í miðtaugakerfi
NO20054343D0 (no) Behandling av immunologiske lidelser ved anvendelse av agonister av interleukin-21/interleukin-21 reseptor
NO20161012A1 (no) Farmasøytisk sammensetning omfattende polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-1,6-dion
DK2045241T3 (da) Fluorsubstituerede cycloalkanoindoler og anvendelse deraf som prostaglandin D2-receptorantagonister
ATE407927T1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
DE60315068D1 (de) Apparat zum unterscheiden von polymorphen von monomorphen tachyarrhythmien
IS8451A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
IS8410A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
DK1812110T3 (da) Apparat til behandling af dermatologiske lidelser
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
IL178575A0 (en) Methods for assessing neurocognitive disorders
NO20054765D0 (no) Nye probiotiske sammensetninger og fremgangsmater for anvendelse derav
IS8526A (is) CRF viðtakamótlyf og aðferðir tengdar þeim
DK1919909T3 (da) Syntesemetoder og mellemprodukter for stereoisomere forbindelser, der er anvendelige til behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet
ITPR20040072A1 (it) Apparato e procedimento per rinfrescare ambienti.
TWI315669B (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
MXPA03004212A (es) Metodos y aparatos para determinar la elasticidad de arandelas de resorte.
IS8388A (is) Blandan af serótónín endurupptökuhindra og histamín 3 viðtaka mótlyfi, öflugum verka eða hlutaverka
NO20044332L (no) Forbedret fremgangsmate for fremstilling av nevirapine
NO20042500L (no) Chemokin-reseptorantagonister og metoder for anvendelse derav
NO20050885L (no) Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
NO20055138L (no) Autotermisk krakkingsprosess